25462-98-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinecarbonitrile, 2-chloro-6-Methylis used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications, including treatments for infectious diseases, neurological disorders, and other health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Pyridinecarbonitrile, 2-chloro-6-Methylis employed as a precursor in the production of pesticides and other crop protection agents. Its chemical properties enable the creation of compounds that can effectively control pests and diseases in agriculture, thereby enhancing crop yields and food security.
Used in Specialty Chemicals Production:
4-Pyridinecarbonitrile, 2-chloro-6-Methylis utilized as a building block in the synthesis of specialty chemicals, such as dyes, pigments, and other performance-enhancing additives. Its versatile structure allows for the development of innovative products with unique properties and applications in various industries.
Used in Organic Synthesis:
As a versatile organic compound, 4-Pyridinecarbonitrile, 2-chloro-6-Methylis employed in organic synthesis for the preparation of other complex organic molecules. Its reactivity and functional groups make it a valuable component in the synthesis of various compounds with potential applications in research, industry, and medicine.

Upstream product

• 26413-58-1 2-chloro-6-methyl-4-pyridinecarbonyl chloride 
• 25462-85-5 2-chloro-6-methylpyridine-4-carboxylic acid 
• 25462-95-7 2-Chlor-6-methyl-isonicotinsaeureamid 
• 1112181-60-8 N-tert-butyl-2-chloro-6-methyl-pyridine-4-carboxamide 

Downstream Products

• 1112174-77-2 N-(4-fluoro-3-methoxybenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-59-0 N-(4-fluoro-3-(trifluoromethyl)benzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-56-7 N-(4-fluoro-3-methylbenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-53-4 N-(3,4-difluorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-31-8 N-(3-(trifluoromethyl)benzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-40-9 N-(3-methylbenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-37-4 N-(3-chlorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-95-4 N-(4-fluorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)-methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112182-62-3 4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinic acid 
• 1112173-02-0 trans-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methyl-pyridin-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylic acid 
• 1112171-88-6 N-(3-methoxybenzyl)-4-(2-(((cis)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112182-36-1 tert-butyl (cis)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylcarbamate 
• 1112171-08-0 N-(3-methoxybenzyl)-4-(2-(((trans)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 

Relevant academic research and scientific papers

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.

NOVEL DGAT2 INHIBITORS

The present invention provides compounds of the Formula below: [Formula should be inserted here] Where A, X, R, and R2-R3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and

HETEROARYLS AND THEIR USE AS PI3K INHIBITORS

This invention provides compounds of formula (IA) or (IB): wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS

Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis

Potent, highly selective and orally-bioavailable MMP-13 inhibitors have been identified based upon a (pyridin-4-yl)-2H-tetrazole scaffold. Co-crystal structure analysis revealed that the inhibitors bind at the S1′ active site pocket